Insulet stock stood at USD 141.10 on October 16, 2026, 60.24 percent below 52-week high
Published on 10/17/2026 at 21:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRange and results
- On October 16, 2026, Insulet stock sat 60.24 percent below its 52-week high.
- In the second quarter of 2026, revenue rose 23.50 percent to USD 801.70 million.
- Insulet stock stood at USD 141.10 on October 16, 2026 at 4:00 p.m. ET, plus 1.68 percent versus the Nasdaq prior close of USD 138.77.
- Insulet will report third-quarter results on November 4, 2026.
Insulet stock (ISIN US45784P1012) stood at USD 141.10 on October 16, 2026, leaving the price 60.24 percent below its 52-week high of USD 354.88. In the second quarter of 2026, revenue rose 23.50 percent to USD 801.70 million, according to ScanX. The latest completed Nasdaq session left the stock at USD 141.10 at 4:00 p.m. ET, plus 1.68 percent versus the Nasdaq prior close of USD 138.77.
Revenue growth remains visible
The second-quarter revenue increase came with adjusted earnings per share of USD 1.66, up 41.50 percent from USD 1.17 in the year-ago quarter. Insulet also reported adjusted operating margin of 72.90 percent for the period, up 3.20 percentage points year over year, according to ScanX.
Price stays below the yearly high
Insulet's USD 141.10 price was USD 14.70 above the 52-week low of USD 126.40 and USD 213.78 below the high on October 16, 2026. Trading volume reached 1,618,208 shares, compared with an average volume of 1,695,098 shares. The price therefore sat 11.63 percent above the yearly low and 60.24 percent below the yearly high.
Valuation and next reporting date
Insulet had a market capitalization of USD 9.8 billion and a trailing P/E ratio of 26.37 on October 16, 2026. The company said it will report third-quarter 2026 results on November 4, 2026, before the market opens, according to Insulet.
Comparison with peers
Insulet (NASDAQ, USD): plus 1.68 percent, P/E 26.37, market capitalization USD 9.8 billion
DexCom (NASDAQ, USD): minus 1.90 percent, P/E 34.01, market capitalization USD 32.5 billion
Tandem Diabetes Care (NASDAQ, USD): minus 1.69 percent, P/E minus 17.49, market capitalization USD 1.1 billion
Where the stock stands
Insulet's latest completed Nasdaq price placed the company between its yearly low and high, while its second-quarter revenue growth remained above 20.00 percent. The next scheduled reporting date is November 4, 2026, when investors will receive the third-quarter update.
Insulet stock facts
- Company: Insulet Corporation
- ISIN: US45784P1012
- Ticker: PODD
- Primary exchange: Nasdaq
- Price Nasdaq (as of October 16, 2026, 4:00 p.m. ET): USD 141.10
- Change versus Nasdaq prior close: plus 1.68 percent
- Nasdaq prior close (October 16, 2026): USD 138.77
- Market capitalization: USD 9.8 billion (as of October 16, 2026)
- 52-week range: USD 126.40-354.88 (as of October 16, 2026)
- Sector / Industry: Health care / Medical devices
- Next earnings date: November 4, 2026
Market context: Market report Nasdaq Composite.
